Pre-earnings brief
Reports
Thu, Apr 30, 2026
Est. EPS
—
Est. revenue
—
Implied move
±15.3%
EPS beat rate
75%
Hologic, Inc. is a health care company that specializes in developing medical devices and diagnostics, particularly in women's health. As a player in the health care equipment sector, Hologic's innovations are crucial for improving patient outcomes and addressing various health issues, making it a significant contributor to the health care landscape.
Last quarter
In the last quarter, Hologic reported an EPS of $1.04, falling short of expectations by 4.5%. The stock reacted slightly negatively, indicating some investor disappointment.
EPS beat streak
0Q
EPS beat rate
75%
Avg EPS surprise
-1.56%
Avg 1-day reaction
+0.13%
Overall, expectations for Hologic's upcoming earnings are mixed, with uncertainty surrounding revenue and profitability metrics. Investors are keen to see if the company can regain momentum after a slight earnings miss last quarter.
Bull case
The optimistic view hinges on Hologic's ability to show strong revenue growth and improved margins, suggesting a rebound in demand for its health care products.
Bear case
The pessimistic outlook is based on concerns about ongoing market challenges and potential supply chain issues that could hinder revenue growth.
The print will turn on these.
Q1
What will be the EPS for this quarter, and how does it compare to previous quarters?
EPS is a critical measure of profitability, and a significant change could impact investor sentiment and stock performance.
Q2
What are the expectations for revenue growth in key product segments?
Understanding revenue growth in specific areas will help gauge the company's market position and future prospects.
Why consensus could be wrong
The Street may be underestimating Hologic's ability to recover from recent challenges, particularly in its key product lines.
Supporting evidence
Hologic has a strong track record of beating EPS estimates, with a 75% beat rate over the last eight quarters.
The options market is pricing a larger move than historical averages, suggesting that traders expect significant volatility.
Recent trends in the health care sector indicate a rebound in demand for medical devices.
Key risk
If the EPS comes in above $1.10, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a miss last quarter, and investors are looking for signs of recovery.
Bull confirmed if
An EPS of $1.10 or higher would confirm the bull case, indicating a recovery in profitability.
Bear confirmed if
An EPS below $1.00 would confirm the bear case, raising concerns about ongoing operational challenges.
What the market is pricing for the move.
Implied Move
±15.32%
Historical Avg
±1.1%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.
Options are pricing ±15.3% while HOLX has averaged ±1.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.2%
30d HV
2.7%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.2% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Hologic beats expectations, history suggests the stock could see a modest positive reaction, confirming a recovery narrative.
In line / cautious
If results are in line with expectations, the stock may react neutrally, reflecting cautious sentiment among investors.
Miss
A miss could lead to a negative reaction, with history suggesting an average decline of around 0.76%.
The lines on the call that would change the story.
—
Est. EPS
$1.36
Est. Rev
$1.9B
Impl. Move
±7.8%